These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 15329216)

  • 1. [Analyzing clinical character of patients resistant to lamivudine with chronic hepatitis B with YMDD mutations or non-YMDD mutations].
    Yang DH; Xie YJ; Liang WF; Zhao NF
    Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):496-7. PubMed ID: 15329216
    [No Abstract]   [Full Text] [Related]  

  • 2. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
    Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
    Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of core promoter mutations with viral breakthrough in chronic hepatitis B patients on long-term lamivudine therapy.
    Kazim SN; Chauhan R; Das BC; Sarin SK
    J Gastroenterol Hepatol; 2006 Oct; 21(10):1525-32. PubMed ID: 16928212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of breakthrough hepatitis due to lamivudine-resistant hepatitis B virus by a sensitive semiquantitative assay using peptide nucleic acids.
    Mori K; Minami M; Kirishima T; Kunimoto K; Okita M; Nakayama M; Makiyama A; Yamaoka J; Nakajima T; Yasui K; Itoh Y; Okanoue T
    Intervirology; 2006; 49(5):274-80. PubMed ID: 16714856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: a single center experience.
    Sun J; Wang Z; Ma S; Zeng G; Zhou Z; Luo K; Hou J
    J Med Virol; 2005 Mar; 75(3):391-8. PubMed ID: 15648063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of lamiduvine-resistant mutant chronic hepatitis B with interferon alpha].
    Pariente A; Tachet A; Poveda JD
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1059-60. PubMed ID: 12483147
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants.
    Suzuki F; Akuta N; Suzuki Y; Sezaki H; Arase Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kobayashi M; Matsuda M; Satoh J; Watahiki S; Kumada H
    J Med Virol; 2006 Mar; 78(3):341-52. PubMed ID: 16419116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical study of oligonucleotide microarray on monitoring the lamivudine-resistance mutations in hepatitis B virus].
    Song JW; Lin JS; Kong XJ; Liang KH
    Zhonghua Gan Zang Bing Za Zhi; 2003 Jun; 11(6):361-3. PubMed ID: 12837218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Events occurring at the time of breakthrough hepatitis during lamivudine treatment for chronic hepatitis B.
    Yokosuka O
    J Gastroenterol; 2004 Aug; 39(8):813-4. PubMed ID: 15338383
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
    Marrone A; Zampino R; Karayannis P; Cirillo G; Cesaro G; Guerrera B; Ricciotti R; del Giudice EM; Utili R; Adinolfi LE; Ruggiero G
    Aliment Pharmacol Ther; 2005 Oct; 22(8):707-14. PubMed ID: 16197491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How do naturally occurring YMDD-motif mutants influence the clinical course of lamivudine-naïve patients with chronic hepatitis B virus infection?
    Tsubota A
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1769-71. PubMed ID: 17074012
    [No Abstract]   [Full Text] [Related]  

  • 12. YMDD motif variants in inactive hepatitis B carriers detected by Inno-Lipa HBV DR assay.
    Akarsu M; Sengonul A; Tankurt E; Sayiner AA; Topalak O; Akpinar H; Abacioglu YH
    J Gastroenterol Hepatol; 2006 Dec; 21(12):1783-8. PubMed ID: 17074014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predominance of hepatitis B virus YMDD mutants is prognostic of viral DNA breakthrough.
    Lee CH; Kim SO; Byun KS; Moon MS; Kim EO; Yeon JE; Yoo W; Hong SP
    Gastroenterology; 2006 Apr; 130(4):1144-52. PubMed ID: 16618409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel accurate ACRS-PCR method with a digestion internal control for identification of wild type and YMDD mutants of hepatitis B virus strains.
    Hosseini SY; Sabahi F; Amini-Bavil-Olyaee S; Alavian SM; Merat S
    J Virol Methods; 2006 Nov; 137(2):298-303. PubMed ID: 16962669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study.
    Akuta N; Suzuki F; Suzuki Y; Sezaki H; Hosaka T; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Kumada H
    J Med Virol; 2005 Apr; 75(4):491-8. PubMed ID: 15714490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of HBV gene variations on disease development and antiviral therapy for patients with chronic hepatitis B.
    Chen JY; Wang LW; Sun XM; Gong ZJ
    Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):393-7. PubMed ID: 16109523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
    Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
    J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.
    Lindh M; Hannoun C; Malmström S; Lindberg J; Norkrans G
    J Clin Microbiol; 2006 Jul; 44(7):2587-9. PubMed ID: 16825388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural infection of HBV DNA YMDD variant strains in a chronic hepatitis B patient before treatment with lamivudine.
    Yang DH; Liang WF; Zhao NF; Xie YJ
    Hepatobiliary Pancreat Dis Int; 2002 Nov; 1(4):539-40. PubMed ID: 14607683
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term follow-up of chronic hepatitis B after the emergence of mutations in the hepatitis B virus polymerase region.
    Natsuizaka M; Hige S; Ono Y; Ogawa K; Nakanishi M; Chuma M; Yoshida S; Asaka M
    J Viral Hepat; 2005 Mar; 12(2):154-9. PubMed ID: 15720530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.